Pharmaceutical industry sponsorship and research outcome and quality: systematic review

被引:1426
作者
Lexchin, J [1 ]
Bero, LA
Djulbegovic, B
Clark, O
机构
[1] York Univ, Sch Hlth Policy & Management, N York, ON M3J 1P3, Canada
[2] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94118 USA
[3] Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94118 USA
[4] Univ S Florida, Interdisciplinary Oncol Program, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[5] Inst Radium Campinas, BR-13075460 Campinas, SP, Brazil
来源
BMJ-BRITISH MEDICAL JOURNAL | 2003年 / 326卷 / 7400期
关键词
D O I
10.1136/bmj.326.7400.1167
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To investigate whether funding of drug studies by the pharmaceutical industry is associated with outcomes that are favourable to the funder and whether the methods of trials funded by pharmaceutical companies differ from the methods in trials with other sources of support. Methods Medline (January 1966 to December 2002) and Embase (January 1980 to December 2002) searches were supplemented with material identified in the references and in the authors' personal files. Data were independently abstracted by three of the authors and disagreements were resolved by consensus. Results 30 studies were included. Research funded by drug companies was less likely to be published than research funded by other sources. Studies sponsored by pharmaceutical companies were more likely to have outcomes favouring the sponsor than were studies with other sponsors (odds ratio 4.05; 95% confidence interval 2.98 to 5.51; 18 comparisons). None of the 13 studies that analysed methods reported that studies funded by industry was of poorer quality. Conclusion Systematic bias favours products which are made by the company funding the research. Explanations include the selection of an inappropriate comparator to the product being investigated and publication bias.
引用
收藏
页码:1167 / 1170B
页数:6
相关论文
共 66 条
  • [61] Relation between agendas of the research community and the research consumer
    Tallon, D
    Chard, J
    Dieppe, P
    [J]. LANCET, 2000, 355 (9220) : 2037 - 2040
  • [62] Thomas PS, 2002, LANCET, V359, P351, DOI 10.1016/S0140-6736(02)07506-2
  • [63] Vandenbroucke JP, 2000, BRIT MED J, V320, P381
  • [64] Wahlbeck K, 1999, BRIT MED J, V318, P465
  • [65] USE AND SOURCES OF MEDICAL KNOWLEDGE
    WYATT, J
    [J]. LANCET, 1991, 338 (8779) : 1368 - 1372
  • [66] The association between funding by commercial interests and study outcome in randomized controlled drug trials
    Yaphe, J
    Edman, R
    Knishkowy, B
    Herman, J
    [J]. FAMILY PRACTICE, 2001, 18 (06) : 565 - 568